中國的一項新發明可能讓眼鏡過時！近視不是不可逆！中國科研打破常識，未來可能不用戴眼鏡？

———————— 歡迎訂閱、點讚、留言 ——————————

我是司馬華鵬，關注我，每天看到中國科技發展的最新成果。
I'm Huapeng Sima, Follow me for the latest achievements of China's scientific and technological development every day.

大眾普遍認為近視屬於不可逆狀態，重複低強度 650 奈米紅光療法，透過改善眼底脈絡膜供血，強化鞏膜組織，臨床實驗顯示可以顯著抑制兒童眼軸增長，部分受試者出現眼軸測量縮短的情況。眼鏡僅能完成視力矯正屬治標手段，紅光療法嘗試作用於近視發生的底層機制。影片客觀梳理技術局限：對成人尚缺少大規模臨床證據，存在停療反彈疑慮，長期遠期安全數據仍需累積；市場劣質設備泛濫，國家將其劃歸第三類醫療器械強化監管。同時對比低濃度阿托品、戶外光照等防控路徑，剖析眼鏡產業的商業邏輯；指出該技術來自公共衛生需求驅動，短期無法完全取代眼鏡，但重新打開近視干預的全新思考方向。

The public generally believes myopia is irreversible. Repeated low‑intensity 650‑nm red‑light therapy improves choroidal blood‑supply in the fundus and strengthens scleral tissue. Clinical trials show it can significantly slow children’s axial‑eye‑growth, and measurable axial‑shortening has been observed in some subjects. Eyeglasses only correct vision as a symptomatic solution, while red‑light therapy tries to act on the underlying mechanism of myopia. This video objectively sorts out technical limitations: large‑scale clinical evidence for adults is insufficient; treatment‑stop rebound concerns exist; long‑term safety data still need accumulation. Poor‑quality devices flood the market, and national authorities classify it as Class‑III medical‑device for stricter supervision. It also compares prevention approaches including low‑concentration atropine and outdoor‑light exposure, and analyzes the business‑logic of the eyeglass‑industry. Driven by public‑health‑demands, this technology cannot fully replace eyeglasses in the short‑term, yet it opens new perspectives for myopia‑intervention.

相关联账号
- 矽基大司馬：https://www.youtube.com/@%E7%A1%85%E5%9F%BA%E5%A4%A7%E5%8F%B8%E9%A9%AC
- 科技大司馬：https://www.youtube.com/@%E7%A7%91%E6%8A%80%E5%A4%A7%E5%8F%B8%E9%A9%AC
- 大司馬聊科技：https://www.youtube.com/@%E5%A4%A7%E5%8F%B8%E9%A9%AC%E8%81%8A%E7%A7%91%E6%8A%80
- 大司馬談科技：https://www.youtube.com/@%E5%A4%A7%E5%8F%B8%E9%A9%AC%E8%B0%88%E7%A7%91%E6%8A%801

#科技大司马 #科技 #中华文化科普 #民生科普 #社会观察 #人工智能